NASDAQ Recent Insider Buying: Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Equinix Inc (NASDAQ:EQIX), AspenBio Pharma (NASDAQ:APPY)

Technology Stocks News 14

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Kovner Bruce purchased 1,250,000 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 1.01% in last session and finished the day at $4.01. Traded volume was 1.90million shares in the last session and the average volume of the stock remained 2.58million shares. The beta of the stock remained 2.93. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) insider ownership is 6.00%.

Repligen Corporation (NASDAQ:RGEN)’s share were purchased by Jefferies Group with target price of $17.00 that occurred on Tuesday, April 15th. Repligen Corporation (NASDAQ:RGEN) dropped -1.14 percent to $15.66 Monday on volume of 900,669.00million shares. The intra-day range of the stock was $15.47 to $15.84. Repligen Corporation (NASDAQ:RGEN) has a market capitalization of $501.74million.

Equinix Inc (NASDAQ:EQIX) major shareholder Advisory Corp Spo purchased 71,900 shares of the company’s stock on the open market in a transaction dated Wednesday, April 16th. The stock was purchased at an average cost of $171.70 per share, with a total value of $12,345,230.00. Equinix Inc (NASDAQ:EQIX)’s stock on Apr 21, 2014 reported a increase of 0.75% to the closing price of $180.31. Its fifty two weeks range is $152.82 -$231.56. The total market capitalization recorded $8.91billion. The overall volume in the last trading session was 651,548.00million shares. In its share capital, EQIX has million outstanding shares.

AspenBio Pharma (NASDAQ:APPY) SVP Donald R. Hurd purchased 35,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $2.04 per share, with a total value of $71,400.00. AspenBio Pharma (NASDAQ:APPY) SVP Donald R. Hurd purchased 35,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $2.04 per share, with a total value of $71,400.00. On Monday, shares of AspenBio Pharma (NASDAQ:APPY) dropped -2.24% to close the day at $2.18. Company monthly performance is recorded as -25.60%. AspenBio Pharma (NASDAQ:APPY) quarterly revenue growth is -20.44%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone